BLGO
BioLargo, Inc.·Basic Materials
0.15
2.747%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.1452W H: $0.26
BLGO NEWS
accessnewswire.com
Apr 1
BioLargo CEO Dennis Calvert to Present Global Environmental Leadership Award to Robert Bilott at Nassau County PFAS Forum
BioLargo sponsors legal and technical forum on PFAS contamination; company's PFAS remediation technology to be featured on a technical panel alongside leading environmental engineering firms, followed by a special screening of the film "Revealed: How to Poison a Planet." WESTMINSTER, CA / ACCESS Newswire / April 1, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, today announced that CEO Dennis P.
seekingalpha.com
Mar 5
BioLargo, Inc. (BLGO) Q4 2025 Earnings Call Transcript
BioLargo, Inc. (BLGO) Q4 2025 Earnings Call Transcript
accessnewswire.com
Mar 5
BioLargo Reports Annual 2025 Operating and Financial Results
A Year of Disciplined Execution as BioLargo Gained Commercialization for Several Business Segments with $3.9 Million Cash Balance at Year End WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that its Annual Report for the year ended December 31, 2025. To view the filing in its entirety, please see: https://www.biolargo.com/sec-filings BioLargo, Inc. President and CEO Dennis P.
accessnewswire.com
Mar 4
BioLargo Q4 2025 and Year End Earnings Results Webcast and Conference Call on Thursday, March 5th, 2026 - 12:00 PM Eastern Time
WESTMINSTER, CALIFORNIA / ACCESS Newswire / March 4, 2026 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Thursday, March 5th, 2026, at 9:00 am Pacific / 12:00 pm Eastern. The event, which will be open to the public, will be held to review the company's financial results for the three months ending December 31st, 2025, discuss recent milestones, and conduct a question-and-answer session.
accessnewswire.com
Feb 18
BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium
Clinical Experience Presented at Boswick Symposium Shows Rapid Wound Transformation, Enhanced Healing, and Strong Antimicrobial Performance Across Multiple Wound Types WESTMINSTER, CALIFORNIA / ACCESS Newswire / February 18, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, today announced that clinical experience with ViaCLYR™, Clyra Medical Technologies' advanced wound irrigation solution powered by its proprietary Clyrasept™ technology, was presented on January 28 by Dr. Marcus Gitterle, a respected Key Opinion Leader in wound care, at the Boswick Symposium, held January 24-30 in Maui, Hawaii. Dr. Gitterle, who serves as Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy for the Christus Santa Rosa Hospital System in San Antonio, Texas, and Co-founder and Chief Medical Officer of Wound Centrix LLC, presented clinical results from a multi-site evaluation involving approximately 36 cases across four wound clinics over a four-month period.
accessnewswire.com
Feb 9
BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution
Initial Distribution Launch Marks Transition to Revenue-Generating Operations WESTMINSTER, CALIFORNIA / ACCESS Newswire / February 9, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, announced today that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order from Advanced Solution, LLC for ViaCLYR™, Clyra's FDA-cleared wound irrigation solution. The order marks the start of commercial distribution and represents Clyra's transition from development-stage operations to early revenue generation.
